Tenax Therapeutics (TENX) Non Operating Interest Expenses (2010 - 2024)

Tenax Therapeutics has disclosed Non Operating Interest Expenses across 10 years of filings, most recently posting -$1000.0 for Q4 2024.

• In Q4 2024, Non Operating Interest Expenses fell 145.72% year-over-year to -$1000.0; the TTM figure through Dec 2024 stood at $23000.0 (down 4.17% YoY), while the FY2024 annual figure was $23000.0, down 4.17% from the prior year.
• Non Operating Interest Expenses came in at -$1000.0 for Q4 2024 at Tenax Therapeutics, down from $7000.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $9126.0 in Q2 2023 to a low of -$1000.0 in Q4 2024.
• Average Non Operating Interest Expenses over 5 years is $3299.6, with a median of $2387.0 recorded in 2022.
• Year-over-year, Non Operating Interest Expenses jumped 1334.68% in 2023 and tumbled 145.72% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at $2643.0 in 2020, then plunged by 87.29% to $336.0 in 2021, then grew by 10.71% to $372.0 in 2022, then jumped by 487.9% to $2187.0 in 2023, then plunged by 145.72% to -$1000.0 in 2024.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were -$1000.0 in Q4 2024, $7000.0 in Q3 2024, and $9000.0 in Q2 2024.